In the lawsuit, Vertex Pharmaceuticals challenged an oral opinion issued by the Health and Human Services Office of the Inspector General that its fertility support program would violate federal ...

A Vertex Pharmaceuticals therapeutic candidate designed to avoid immunosuppression has fallen short of its efficacy goals in a clinical trial, leading the drugmaker to discontinue the program.

As Vertex looks to tap into the Middle Eastern market of around 23,000 patients—on top of its estimated patient pool of 35,000 in the U.S. and Europe—the drugmaker remains “confident in our ...

Vertex Pharmaceuticals on Monday reported disappointing first-quarter earnings impacted by weaker-than-expected sales of its drugs for cystic fibrosis, and little or no contributions from a gene ...

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved the expanded use of TRIKAFTA ® (elexacaftor ...

That’s the opinion of top Vertex Pharmaceuticals executives and several market analysts about the Boston-based company’s painkiller Journavx, which the Food and Drug Administration approved on ...